Midlothian surgeon gets early access to Johnson & Johnson’s newest cataract lens

Dr. Deepak Sobti of Texas Eye and Cataract is among the first 30 U.S. surgeons with pre-market access to Johnson & Johnson’s TECNIS PureSee IOL, which he began offering to eligible cataract patients in June 2026. The lens is designed to expand vision range after surgery while preserving contrast sensitivity, giving patients in Midlothian and Ellis County early access to a newly FDA-approved technology.

Why it matters: - Texas Eye and Cataract patients in Midlothian now have access to one of the first new cataract lens options to reach the U.S. market after FDA approval. - The TECNIS PureSee IOL is designed to improve vision after cataract surgery while reducing dependence on glasses. - Cataracts remain the leading cause of vision loss worldwide and affect millions of Americans, especially people older than 60.

What happened: - Dr. Deepak Sobti, MD, joined a select group of 30 U.S. surgeons with early access to Johnson & Johnson’s TECNIS PureSee IOL. - Dr. Sobti began offering the lens to eligible cataract surgery patients at the beginning of June 2026. - Texas Eye and Cataract is based in Midlothian, Texas, and serves the surrounding area.

The details: - The TECNIS PureSee IOL received FDA approval in March 2026. - The lens is the first and only FDA-approved extended depth of focus IOL that maintains contrast sensitivity comparable to a standard monofocal lens. - Contrast sensitivity affects the ability to distinguish objects from their backgrounds, especially in low-light or foggy conditions. - The lens uses a purely refractive design. - The design extends range of vision without the halos or glare sometimes linked to older lens technologies. - Clinical data showed 97% of patients reported no very bothersome visual disturbances. - Clinical data also showed 97% of patients said they would recommend the lens to friends or family. - The lens is designed to deliver strong distance and intermediate vision with meaningful near vision. - Nearly half a million eyes worldwide have already benefited from the TECNIS PureSee IOL. - The lens has been available in Europe and Canada before reaching U.S. patients. - Dr. Sobti is the head cataract surgeon and founder of Texas Eye and Cataract. - Dr. Sobti said the clinic is grateful to provide world-class care in Midlothian and Ellis County and is excited about the outcomes the new technology may help achieve. - Patients can schedule a consultation with Texas Eye and Cataract at (469) 505-2020 or through the clinic’s website. - Texas Eye and Cataract is located at 2251 Freeman Lane, Suite 100, Midlothian, Texas.

Between the lines: - Early U.S. access suggests the lens is entering the market through a limited rollout before broader availability. - The emphasis on contrast sensitivity and fewer visual side effects addresses two of the biggest tradeoffs patients and surgeons face with premium cataract lenses. - Access in a suburban North Texas community signals that advanced eye-care technology is moving beyond major academic centers.

What’s next: - Patients who may be candidates can consult with Texas Eye and Cataract to determine whether the TECNIS PureSee IOL is a fit for their surgery. - Wider U.S. availability is expected after the early-access phase expands. - More cataract patients in the region may gain access as surgeons adopt the new lens following FDA approval.

The bottom line: - Dr. Sobti’s early access puts Midlothian patients among the first in the country to benefit from a newly approved cataract lens aimed at sharper vision with fewer optical tradeoffs.